3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
335
Pemetrexed
276
Cisplatin
228
Paclitaxel
193
pembrolizumab
178
Erlotinib Hydrochloride
173
Docetaxel
154
Gemcitabine
126
Nivolumab
112
Bevacizumab
112
Radiotherapy
84
Etoposide
68
durvalumab
62
atezolizumab
59
Ipilimumab
51
Radiosurgery
49
osimertinib
42
130-nm albumin-bound paclitaxel
40
Afatinib
39
Gefitinib
38
Cetuximab
38
Albumin-Bound Paclitaxel
37
Taxes
32
Vinorelbine
29
Radiation
29
Topotecan
28
Drug Therapy
25
Crizotinib
23
Platinum
21
Dexamethasone
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
tinostamustine
×
Thoracic
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts